Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4100511 (DC-853), LY4100511 (DC-853) Dose 1, LY4100511 Dose 1
LY4100511 · 1 trial · 1 indication
Percentage of participants achieving ≥75% reduction from baseline in PASI-75 at Week 12 without use of background antipsoriasis therapy were responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| Arm | Type | Description |
|---|---|---|
| LY4100511 200 mg BID | EXPERIMENTAL | Participants received LY4100511 200 milligrams (mg) administered orally twice daily (BID) for 12 weeks. |
| LY4100511 400 mg BID | EXPERIMENTAL | Participants received LY4100511 400 mg administered orally BID for 12 weeks. |
| LY4100511 800 mg QD | EXPERIMENTAL | Participants received LY4100511 800 mg administered orally once daily (QD) for 12 weeks, with matching placebo administered in the evening. |
| Placebo BID | PLACEBO_COMPARATOR | Participants received placebo administered orally BID for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| LY4100511 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization * Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive). * Must be willing to discontinue topical and/or systemic therapies for psoriasis before the fi...
LY4100511 is being developed for the treatment of moderate-to-severe plaque psoriasis in adults. It is an investigational small molecule studied in a Phase 2 clinical trial that enrolled 222 participants aged 18 years and older across the United States, Canada, Czechia, Germany, Hungary, Japan, and Poland.
LY4100511 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company sponsored the Phase 2 clinical study of the drug in adults with moderate-to-severe plaque psoriasis.
LY4100511 is in Phase 2 clinical development. The Phase 2 trial, NCT06602219, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
LY4100511 has been studied in one clinical trial, NCT06602219, titled "A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis." This completed Phase 2 trial was randomized, double-blind, placebo-controlled, and enrolled 222 participants.
Yes, LY4100511 is also known as DC-853. The Phase 2 trial in moderate-to-severe plaque psoriasis refers to the drug as LY4100511 (DC-853), and the same compound has also been described as LY4100511 (DC-853) Dose 1 and LY4100511 Dose 1 in study documentation.